Andrea Riccardo Filippi1, Mario Levis2, Rahul Parikh3, Bradford Hoppe4,5. 1. Department of Oncology, San Luigi Gonzaga University Hospital, University of Torino, Regione Gonzole 10, 10043, Orbassano, Turin, Italy. andreariccardo.filippi@unito.it. 2. Department of Oncology, San Luigi Gonzaga University Hospital, University of Torino, Regione Gonzole 10, 10043, Orbassano, Turin, Italy. 3. Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, USA. 4. Department of Radiation Oncology, University of Florida, Gainesville, USA. 5. University of Florida Health Proton Therapy Institute, Jacksonville, USA.
Abstract
PURPOSE OF REVIEW: The aim of this article is to discuss the current role of radiotherapy (RT) for early-stage Hodgkin's lymphoma (HL) in the context of risk-adapted and response-adapted treatment strategy, and describe changes in RT technical approach. RECENT FINDINGS: In low-risk patients, RT could be omitted but, at the price of a lower progression-free survival, and its role is still debated. Ongoing trials are combining new agents with chemotherapy alone or response-adapted combined modality therapy, and results are awaited. Modern RT incorporates lower doses and smaller fields, together with the implementation of sophisticated delivery techniques aimed to reducing the dose to critical structures such as the heart. The role of RT for early-stage HL is still under debate, and new combinations are emerging; an individualized approach should be recommended, considering all RT technical opportunities to minimize toxicity while maintaining efficacy.
PURPOSE OF REVIEW: The aim of this article is to discuss the current role of radiotherapy (RT) for early-stage Hodgkin's lymphoma (HL) in the context of risk-adapted and response-adapted treatment strategy, and describe changes in RT technical approach. RECENT FINDINGS: In low-risk patients, RT could be omitted but, at the price of a lower progression-free survival, and its role is still debated. Ongoing trials are combining new agents with chemotherapy alone or response-adapted combined modality therapy, and results are awaited. Modern RT incorporates lower doses and smaller fields, together with the implementation of sophisticated delivery techniques aimed to reducing the dose to critical structures such as the heart. The role of RT for early-stage HL is still under debate, and new combinations are emerging; an individualized approach should be recommended, considering all RT technical opportunities to minimize toxicity while maintaining efficacy.
Entities:
Keywords:
Early stage; Hodgkin’s lymphoma; Proton therapy; Radiotherapy
Authors: Julia Koeck; Yasser Abo-Madyan; Frank Lohr; Florian Stieler; Jan Kriz; Rolf-Peter Mueller; Frederik Wenz; Hans Theodor Eich Journal: Int J Radiat Oncol Biol Phys Date: 2011-11-11 Impact factor: 7.038
Authors: Bradford S Hoppe; Stella Flampouri; Zhong Su; Christopher G Morris; Naeem Latif; Nam H Dang; James Lynch; Zuofeng Li; Nancy P Mendenhall Journal: Int J Radiat Oncol Biol Phys Date: 2011-10-17 Impact factor: 7.038
Authors: Hans Theodor Eich; Volker Diehl; Helen Görgen; Thomas Pabst; Jana Markova; Jürgen Debus; Anthony Ho; Bernd Dörken; Andreas Rank; Anca-Ligia Grosu; Thomas Wiegel; Johann Hinrich Karstens; Richard Greil; Normann Willich; Heinz Schmidberger; Hartmut Döhner; Peter Borchmann; Hans-Konrad Müller-Hermelink; Rolf-Peter Müller; Andreas Engert Journal: J Clin Oncol Date: 2010-08-16 Impact factor: 44.544
Authors: Maja V Maraldo; Bouthaina S Dabaja; Andrea R Filippi; Tim Illidge; Richard Tsang; Umberto Ricardi; Peter M Petersen; Deborah A Schut; John Garcia; Jayne Headley; Amy Parent; Benoit Guibord; Riccardo Ragona; Lena Specht Journal: Int J Radiat Oncol Biol Phys Date: 2015-02-07 Impact factor: 7.038
Authors: Bhishamjit S Chera; Christina Rodriguez; Christopher G Morris; Debbie Louis; Daniel Yeung; Zuofeng Li; Nancy P Mendenhall Journal: Int J Radiat Oncol Biol Phys Date: 2009-04-20 Impact factor: 7.038
Authors: Maja V Maraldo; Marianne C Aznar; Ivan R Vogelius; Peter M Petersen; Lena Specht Journal: Int J Radiat Oncol Biol Phys Date: 2012-11-29 Impact factor: 7.038
Authors: Celalettin Eroglu; Leylagül Kaynar; Okan Orhan; Muzaffer Keklik; Cem Sahin; Oğuz G Yildiz; Selahattin Mentes; Fatih Kurnaz; Dicle Aslan; Serdar Sivgin; Serdar Soyuer; Bülent Eser; Mustafa Cetin; Ali Unal Journal: Am J Clin Oncol Date: 2015-02 Impact factor: 2.339
Authors: Frederika A van Nimwegen; Michael Schaapveld; David J Cutter; Cècile P M Janus; Augustinus D G Krol; Michael Hauptmann; Karen Kooijman; Judith Roesink; Richard van der Maazen; Sarah C Darby; Berthe M P Aleman; Flora E van Leeuwen Journal: J Clin Oncol Date: 2015-11-16 Impact factor: 44.544
Authors: Andrea Riccardo Filippi; Sofia Meregalli; Anna DI Russo; Mario Levis; Patrizia Ciammella; Michela Buglione; Andrea Emanuele Guerini; Giuseppina De Marco; Vitaliana De Sanctis; Stefano Vagge; Umberto Ricardi; Gabriele Simontacchi Journal: Radiat Oncol Date: 2020-03-12 Impact factor: 3.481
Authors: Georgios Ntentas; Katerina Dedeckova; Michal Andrlik; Marianne C Aznar; Rebecca Shakir; Johanna Ramroth; Rubina Begum; Jiří Kubeš; Sarah C Darby; N George Mikhaeel; David J Cutter Journal: Int J Radiat Oncol Biol Phys Date: 2021-11-09 Impact factor: 7.038